0000950170-25-021396.txt : 20250214 0000950170-25-021396.hdr.sgml : 20250214 20250214170004 ACCESSION NUMBER: 0000950170-25-021396 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250214 DATE AS OF CHANGE: 20250214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87614 FILM NUMBER: 25630517 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF ROAD STREET 2: FL 7 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF ROAD STREET 2: FL 7 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Huh Hoyoung CENTRAL INDEX KEY: 0001401267 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SCHEDULE 13G MAIL ADDRESS: STREET 1: C/O NEKTAR THERAPEUTICS STREET 2: 201 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001401267 XXXXXXXX LIVE Ordinary Shares, $0.0001 par value 11/14/2024 0001541157 Akari Therapeutics, Plc 00972G207 22 Boston Wharf Road FL 7 Boston MA 02210 Rule 13d-1(d) Hoyoung Huh, M.D., Ph.D. X1 8294508000 0 8294508000 0 8294508000 N 15.5 IN (1) Comprised of the Registrant's ordinary shares, nominal value $0.0001 per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares. (2) Includes (i) 7,605,994,000 Ordinary Shares and (ii) options to purchase 469,600,000 Ordinary Shares exercisable within 60 days from the date of this report held by the Reporting Person and (iii) 218,914,000 Ordinary Shares held of record by Hannol Ventures LLC. The Reporting Person is the sole member of Hannol Ventures LLC and exercises voting and dispositive power over such 218,914,000 Ordinary Shares. In addition, the Reporting Person holds warrants to purchase 103,482,000 Ordinary Shares (the "Warrants"). All Warrants held by the Reporting Person are held personally in the Reporting Person's name and subject to a 9.99% beneficial ownership limitation. The Reporting Person disclaims beneficial ownership of the Warrants and securities issuable upon exercise of the Warrants to the extent that such exercise would exceed the 9.99% beneficial ownership limitation. (3) The percentage is based on 53,186,919,523 Ordinary Shares issued and outstanding as of February 14, 2025, as per information provided to the Reporting Person by the Issuer. Akari Therapeutics, Plc 22 Boston Wharf Road, 7th Floor, Boston, MA 02210 Hoyoung Huh, M.D., Ph.D. c/o Akari Therapeutics Plc 22 Boston Wharf Road, 7th Floor Boston, MA 02210 U.S. Y 8,294,508,000 15.5 8,294,508,000 0 8,294,508,000 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Hoyoung Huh, M.D., Ph.D. /s/ Hoyoung Huh 02/14/2025